Teva, Mylan Get FDA OK For Zyprexa Generic

Law360, New York (March 29, 2005, 12:00 AM EST) -- Two generic makers have been cleared by the U.S. Food and Drug Administration to sell versions of Eli Lilly & Co.’s bestselling drug, Zyprexa if they prevail in a closely watched federal patent lawsuit.

The U.S. Food & Drug Administration gave the approval to Israel-based Teva Pharmaceutical Industries on Monday and to Pennsylvania-based Mylan Laboratories Inc. on Tuesday.

If a judge finds in favor of generics makers in their patent litigation with Lilly, they could begin to sell generic versions of Zyprexa immediately. However, an appeal...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.